In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 376 to 400 of 441

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]	Technology appraisal guidance	TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]	Technology appraisal guidance	TBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock	Interventional procedures guidance	25 March 2026
Surgical mesh for ventral hernias	Health technology evaluation	TBC
Surgical vessel sealing systems (MT798)	Medical technologies guidance	TBC
Suspected cancer update	Quality standard	TBC
Suspected Cancer: recognition and referral (update)	NICE guideline	25 March 2026
Suspected sepsis: recognition, diagnosis and early management	NICE guideline	TBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]	Technology appraisal guidance	10 June 2027
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413	Technology appraisal guidance	15 July 2026
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]	Technology appraisal guidance	3 December 2025
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]	Technology appraisal guidance	11 February 2026
Tarlatamab for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617	Technology appraisal guidance	TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Technologies to support self-monitoring of vision change for people with macular disease (provisional title)	Health technology evaluation	TBC
Technologies to support the rapid diagnosis of endometriosis (provisional title)	Health technology evaluation	TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance	28 July 2027
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	8 April 2026
Teprotumumab for treating thyroid eye disease [ID6432]	Technology appraisal guidance	TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379	Technology appraisal guidance	25 September 2026
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance	TBC

Results per page

10
25
50
All